GENOMOM - NIPT(Non-Invasive Prenatal Test) Service
Negotiable Min Order Quantity Unit
- Required Quantity
-
- Place of Origin
- South Korea
- Payment Terms
- Negotiable
- Production method
- Negotiable
- Shipping / Lead Time
- Negotiable / Negotiable
- Keyword
- ngs, napt, informatics, non invasive prenatal test
GENOMECARE CO LTD
- Verified Certificate
-
7
| Product name | GENOMOM - NIPT(Non-Invasive Prenatal Test) Service | Certification | - |
|---|---|---|---|
| Category |
Monitoring & Diagnostic Equipment
Other Monitoring & Diagnostic Equipment |
Ingredients | - |
| Keyword | ngs , napt , informatics , non invasive prenatal test | Unit Size | - |
| Brand name | - | Unit Weigh | - |
| origin | South Korea | Stock | - |
| Supply type | - | HS code | - |
Product Information
GENOMOM - NIPT(Non-Invasive Prenatal Test) Service
│ DESCRIPTION │
* Q. What is NGS? NGS stands for “Next Generation Sequencing”, the advanced technology of DNA sequencing with fast, accurate and high output performance.
* Q. What is Genomom for NIPT Method?NIPT is a screening method for detecting certain specific chromosomal abnormalities in a developing baby. After 10 weeks of pregnancy, NIPT can detect whether your baby is at risk of fetal trisomy 13, 18 and 21 (Patau syndrome, Edwards syndrome, and Down syndrome) accurately.
* NIPT Process1. Draw blood sample from pregnant women(From 10weeks)
2. Q.C
3. Library Construction
4. DNA Sequencing
5. Sequencing Data Analysis
6. Detect fetal defect probability
* Accuracy and reliabilityNIPT using next generation sequencing technology have been delivered more accurate results for prenatal test of fetal abnormality since 2012 in US and other advanced personal genome analysis markets. Notable papers were published in major journal such as NATURE, PNAS and still related papers are publishing in main streams. Nevertheless of bit differences, NIPT results maintain over 99% accuracy.
The Newest NGS technologies, chromosomal abnormalities are non-invasively detectable with over 99% confident sensitivity and specificity level. As result, NIPT are now evolving toward favorable and affordable prenatal diagnosis technique. NIPT is a screening method for detecting certain specific chromosomal abnormalities in a developing baby. After 10 weeks of pregnancy, NIPT can detect whether your baby is at risk of fetal trisomy 13, 18 and 21 (Patau syndrome, Edwards syndrome, and Down syndrome) accurately.
NIPT using next generation sequencing technology have been delivered more accurate results for prenatal test of fetal abnormality since 2012 in US and other advanced personal genome analysis markets. Notable papers were published in major journal such as NATURE, PNAS and still related papers are publishing in main streams. Nevertheless of bit differences, NIPT results maintain over 99% accuracy.
B2B Trade
| Price (FOB) | Negotiable | transportation | - |
|---|---|---|---|
| MOQ | Negotiable | Leadtime | Negotiable |
| Payment Options | Negotiable | Shipping time | Negotiable |
- President
- MyungJun Jeong
- Address
- Bdong 4F, Gwanggyuoro 145, Yeongtong-gu, Suwon-si, Gyeonggi-do, KOREA
- Product Category
- Medical Test Kit
- Year Established
- 2012
- No. of Total Employees
- 1-50
- Company introduction
-
We, Genomecare co,Ltd.,are looking for Overseas Sales Partnership as a distributor or an Exclusive Partner(Technology Transfer).
Genomcare is serving NIPT (Non-invasive prenatal Test) &PGS (Pre-implantation genetic Screening) base on NGS(Next generation Sequencing) service to our customer utilizing proton and S5XL (ThermoFisher) which are screening chromosomal abnormalities of Fetus and maternal and performed on Embryo during IVF treatment to screen for numerical chromosomal abnormalities.
We published the clinical results of NIPT in PLOS ONE&BMC Medical Genomics(Oct 2014, April 2016, Oct 2016) worldwide authoritative scientific journal. Through these experiments, Genomecare became the first sacrificially verified NIPT service provider in Korea with world-class level of NGS and data analysis competency.
ION PROTON
The Ion Proton system makes affordable, high-quality next-generation sequencing to elucidate vriants important for the heritability of cancer as well as Mendelian and complex disorders.
Exome sequecning is a targeted sequencing approach that is restricted the protein-coding region of genomes. The exome is estimated to encompass approximately 1% of the genome, yet contains approximately 85% of disease-causing mutations. For genetic researchers trying to unravel the disease-causing genes of over 6,800 rare disease, exome sequencing enables the identification of common single-nucleotide variants(SNVs) and small insertions or deletions (indels), as well as rare de novo mutations that may explain the heritabiltiy of Mendelian and complex disorders.
- Main Markets
-
Indonesia
Philippines
Singapore
South Korea
Thailand
Viet Nam
- Main Product
